药石科技(300725) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period was ¥173,722,435.32, representing a year-on-year growth of 35.38%[9] - Net profit attributable to shareholders was ¥48,160,653.29, reflecting a 17.87% increase year-on-year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,493,506.00, up 20.66% from the same period last year[9] - Basic earnings per share for the period was ¥0.3368, an increase of 17.89% compared to the previous year[9] - The company reported a total comprehensive income of ¥47,637,322.95 for the current period, compared to ¥42,316,316.42 in the previous period, reflecting a growth of 12.5%[62] - The net profit for the year-to-date period was ¥117,431,441.71, compared to ¥95,150,610.68 in the previous year, reflecting an increase of about 23.3%[76] - The net profit for the current period was ¥40,239,454.10, compared to ¥39,782,352.79 in the previous period, reflecting an increase of approximately 1.15%[66] Assets and Liabilities - Total assets at the end of the reporting period reached ¥935,516,845.04, an increase of 22.91% compared to the end of the previous year[9] - Current assets totaled approximately ¥510.69 million, slightly up from ¥509.13 million year-over-year, indicating a marginal increase of 0.31%[35] - Non-current assets reached ¥424.83 million, a substantial increase of 68.49% from ¥252.03 million year-over-year[38] - Total liabilities increased to ¥241.16 million from ¥161.43 million, showing a rise of 49.38%[41] - Owner's equity rose to ¥694.36 million from ¥599.73 million, indicating an increase of 15.77%[44] - Total liabilities increased to ¥281,534,980.22 from ¥157,522,965.28, reflecting a growth of 78.5%[54] - Total assets reached ¥993,975,663.60, up from ¥786,325,024.42, representing a growth of 26.4%[54] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥57,554,507.35, down 35.44% compared to the previous year[9] - Cash flow from operating activities generated ¥57,554,507.35, down 35.5% from ¥89,145,846.49 in the previous period[90] - The net cash outflow from investment activities was -275,005,154.41, worsening from -125,156,940.90 in the previous period[99] - The net cash flow from financing activities was 35,866,149.80, compared to a negative flow of -19,682,258.45 in the previous period, indicating a significant improvement[102] - The total cash and cash equivalents at the end of the period stood at 61,291,934.86, a decrease from 63,811,086.80 in the previous period[102] Research and Development - R&D expenses rose by 76.00% to ¥50,094,028.43, indicating a continued commitment to enhancing research capabilities[26] - Research and development expenses for the current period were ¥20,343,873.60, which is a significant increase from ¥10,166,612.14 in the previous period, indicating a focus on innovation[55] - Research and development expenses increased significantly to ¥17,197,490.24 from ¥8,089,844.08, marking a rise of about 112.5%[66] - The company’s R&D expenses for the year-to-date period were ¥50,094,028.43, significantly higher than ¥28,463,244.49 in the previous year, indicating an increase of approximately 76%[73] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,318[13] - Major shareholder Yang Minmin holds 22.22% of the shares, totaling 31,774,630 shares, with 3,000,000 shares pledged[13] Investment Activities - The company reported an investment loss of ¥861,419.62, a decline of 117.34% due to losses from Huishi[26] - Cash inflow from investment activities totaled ¥694,516,374.45, compared to ¥504,966,955.58, showing a 37.5% increase[90] - The company invested 877,434,000.00 in fixed assets, intangible assets, and other long-term assets, compared to 616,522,500.00 in the previous period, reflecting a 42.3% increase[99] Future Plans - The company has plans for market expansion and new product development, focusing on enhancing its competitive edge in the pharmaceutical sector[40] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[86]